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Abstract
Summary The results of this study suggest that, under the
assumption of same relative risk reduction of fractures in
men as for women, strontium ranelate could be considered a
cost-effective strategy compared with no treatment for the
treatment of osteoporotic men from a Belgian healthcare
payer perspective.
Introduction This study was conducted to estimate the cost-
effectiveness of strontium ranelate in the treatment of oste-
oporotic men.
Methods A previously validated Markov microsimulation
model was adapted to estimate the cost (€2,010) per
quality-adjusted life-year (QALY) gained of strontium rane-
late compared with no treatment. Similar efficacy data on
lumbar spine and femoral neck bone mineral density (BMD)
between men with osteoporosis at high risk of fracture
(MALEO Trial) and postmenopausal osteoporotic women
(pivotal SOTI, TROPOS trials) supports the assumption, in
the base-case analysis, of the same relative risk reduction of
fractures in men as for women. Analyses were conducted,
from a Belgian healthcare payer perspective, in the popula-
tion from the MALEO Trial who is a men population with a
mean age of 73 years, and BMD T-score ≤−2.5 or prevalent
vertebral fracture (PVF).
Results In the MALEO population, strontium ranelate com-
pared with no treatment was estimated at €49,798 and
€25,584 per QALY gained using efficacy data from the
intent-to-treat analysis and the per-protocol analysis includ-
ing only adherent patients, respectively. In men with a BMD
T-score ≤−2.5 or with PVF, the cost per QALY gained of
strontium ranelate fall below thresholds of €45,000 and
€25,000 per QALY gained based on efficacy data from the
entire population of the clinical trial and from the per-
protocol analyses, respectively.
Conclusions The results of this study suggest that, under the
assumption of same relative risk reduction of fractures in
men as for women, strontium ranelate could be considered
cost-effective compared with no treatment for male
osteoporosis.
Keywords Cost-effectiveness . Fractures . Men .
Osteoporosis . Strontium ranelate
Introduction
Osteoporosis in men is increasingly recognized as a major
public health problem [1]. Although osteoporosis is less com-
mon in men than in women, it has been estimated that around
30 % of hip fractures occur in males and one out of five men
aged 60 years will experience an osteoporotic fracture during
their remaining lifetime [2, 3]. In Belgium, the female/male
ratio of hip fractures significantly decreased from 3.12 to 2.97
between 2000 and 2007 and is expected to further decrease to
2.52 by the year 2025 [2]. With increasing life expectancies in
men and higher excess mortality after hip fractures in men
than in women [4], osteoporosis in men will become a large
burden on society and healthcare systems.
Current treatments available for male osteoporosis, how-
ever, remain limited including alendronate, risedronate,
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zoledronate and parathormone [1]. Strontium ranelate has
been primarily developed and approved for the treatment of
postmenopausal osteoporosis. In clinical trials in postmeno-
pausal women with osteoporosis, strontium ranelate has been
shown to be safe and effective in reducing the risk of vertebral
and non-vertebral fractures in a wide scatter of patients, from
osteopenia to very elderly subjects, over a long period (up to
10 years) [5–9]. The cost-effectiveness of strontium ranelate
in postmenopausal women has also been demonstrated in
different settings [10–14].
Recently, strontium ranelate also demonstrated to be ef-
fective for the treatment of male osteoporosis in a multi-
centre randomised controlled trial (i.e., the MALEO Trial)
[15]. Under continuing economic pressure, the assessment
of a new health intervention, however, goes beyond the
three regulatory criteria of quality, safety and efficacy. The
assessment of cost-effectiveness is considered as the fourth
hurdle to market, and plays an increasingly role in health-
care decision making [16]. Many countries have introduced
formal requirements for economic analyses as part of the
pricing or reimbursement decisions [17]. As the economic
value of strontium ranelate in populations of men has not
been analysed yet, this study aims to estimate the cost-
effectiveness of strontium ranelate, compared with no treat-
ment, for the treatment of Belgian men with osteoporosis or
a prevalent vertebral fracture (PVF).
Materials and methods
Economic model
The simulation model is the same as the model developed
for postmenopausal osteoporotic (PMO) women which has
been validated [18] and used in many published health
economic analyses [12, 13, 19–23]. Recently, an updated
version of the model using a 6-monthcycle length has been
developed [23]. This last model version was slightly revised
in this study to also include a health state for venous throm-
boembolic events (VTEs). The model was programmed
using the software TreeAge Pro 2011 (TreeAge Pro Inc.,
Williamston, MA, USA).
The Markov model health states are no fracture, death,
VTE, hip fracture, clinical vertebral fracture, wrist fracture,
other fracture and the corresponding post-fracture states.
Post-fracture states were created as some parameters (e.g.,
fracture disutility) were estimated over a 1-year period [23].
All patients, one at a time, began in the ‘no fracture’ state
and had, every 6 months, a probability of having a fracture
at the hip, clinical vertebrae, wrist, or other site or of dying.
Patients in a fracture state can stay in the same fracture state
if they re-fracture, change to another fracture state, die or
change in the next cycle to the post-fracture state. Because
hip fracture is associated with extra costs in the year follow-
ing the fracture that are greater than the hospitalization cost
of any other fractures, patients who have had a hip fracture
were only at risk for another hip fracture or dying in the first
cycle following the fracture. Patients being in any post-
fracture state might have a new fracture (all fracture types
are possible), die or move to the ‘no fracture’ state. The
probability for patients to move to the VTE health state was
also considered under treatment with strontium ranelate.
Fracture data
A description of the different components of the model is
provided below. Model data are included in Table 1.
Readers are also referred to previously published research
for further details and limitations of the model [17].
The incidence of hip fractures in the general men popu-
lation was derived from the national database of hospital
bills (average of the years 2005–2007) [2]. Since the inci-
dence of other fractures was not known, we assumed that the
age-specific ratio of index fracture to hip fracture in
Belgium was the same as found in Sweden [3]. This as-
sumption, used in the development of many FRAX® models
including Belgium [24], appears to be appropriate for West
European countries, the USA and Australia [25].
Age-specific mortality rates were obtained from the
National Institute of Statistics. According to data from a
recent meta-analysis [4], hip fractures increased male death
probabilities by 5.75 in the first 6 months following the
fracture, by 2.315 in the period 6–12 months and by 1.691
in subsequent years. As the increased mortality following
clinical vertebral fractures has been found in many studies to
be very similar than those of a hip fracture [26–29], the
same impact was assumed after hip and clinical vertebral
fractures. To avoid an overestimation of the beneficial effect
of treatment on mortality, it is important to take only into
account excess mortality that are directly or indirectly at-
tributable to the fractures themselves [30], which could be
reduced through fracture prevention. Because excess mor-
tality may also be attributable to comorbidities, we assumed
in the model only 25 % of the excess mortality after frac-
tures [28, 31].
A healthcare payer perspective including direct medical
costs was adopted for all cost estimates, as recommended
for pharmacoeconomic evaluations in Belgium [32].
Following the guideline, direct healthcare costs paid by the
national health insurance and patient's out-of pocket costs
were included [32]. All costs were expressed in the year
2010 using the healthcare product price index when neces-
sary, and discount rates of 3 % for costs and of 1.5 % for
health benefits were assumed for the base-case analysis also
based on the Belgian guideline for pharmacoeconomic eval-
uations [32]. The direct hospitalisation cost of hip fracture,
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administrated in the first cycle following the fracture, was
retrieved from the Belgian national database of hospital bills
for the year 2007 [33]. It included the social security cost
and the patient out-of-pocket contribution for nursing and
residential fees costs only. Extra costs in the year following
the hip fracture were derived from the study of Autier et al.
[34], which based on a prospective controlled study includ-
ing 159 women. These costs, estimated at €8,001 (expressed
in €2,010), were equally distributed between the two first
cycles following the fracture. Hip fractures are also associ-
ated with long-term costs. They were based on the propor-
tion of men being institutionalized following the fracture,
ranging from 6 % (for men aged 60 years) to 65 % (for those
aged over 90 years) [35]. Because men might be institution-
alized later in life, regardless of their hip fracture, an adjust-
ment was made to only include long-term costs attributable
to the fracture itself (see Hiligsmann et al. [18] for further
explanations). The cost of non-hip fractures has never been
estimated in Belgian men and these were quantified relative
to hip fracture cost [36]. So, the costs of clinical vertebral,
wrist and other fracture represent 17.4 %, 14.5 % and
17.4 % of the hip fracture cost, respectively. Non-hip frac-
tures were not associated with long-term costs.
Utility values in the general men population as well as
relative reductions due to fractures in the year following the
fracture and in subsequent years were derived from a sys-
tematic review, which suggested reference values for
countries that do not have their own database [37]. The
reduction of quality-adjusted life-year (QALY) depends on
fracture site but also on the number of prior fractures [18]. In
the case of an occurrence of a second fracture at the same
site, the impact of the first fracture event was reduced by
50 % [18]. For example, if a men with a prior hip fracture
suffered another fracture, the relative reduction of utility
attributable to the first hip fracture was then 0.95. For an
individual with both a hip and vertebral clinical fracture, the
total impact on QALY was assumed to be equal to the sum
of the impacts related to each of the fractures. This last
assumption is consistent with the study of Tosteson et al.
[38], who suggested that the impact of the two fractures is
even greater than the sum of the impacts related to each of
the fractures. The model, however, does not simulate mul-
tiple fractures per 6-monthcycle.
Patient groups
Analyses were conducted in the population from the MALEO
Trial corresponding to men with mean age of 73 years, and
with a bone mineral density (BMD) T-score below the thresh-
old value for osteoporosis (i.e., BMD T-score ≤−2.5) or PVFs
at baseline, in order to match the two populations for whom
postmenopausal osteoporosis medications are currently reim-
bursed in Belgium and in most European countries. The
MALEO Trial included in the Full Analysis Set (FAS) 243
men aged 65 to 90 years with osteoporosis as assessed by a
mean lumbar spine BMD T-score of −2.7 [15]. The mean
BMD at the femoral neck was 0.627 (g/cm2), which corre-
sponds to a T-score of approximately −2.2.
The incidence of fracture in the general population has to
be adjusted to accurately reflect the fracture risk in these
populations. The relative risks of fracture were calculated
from the BMD and the prevalence of vertebral fracture in
the target patient groups. The relative risk for BMD was
calculated using a method previously described [25]. This
method estimates the risk of individuals at a threshold value
or below a threshold value in comparison with that in the
general population. BMD values at the femoral neck were
derived from the National Health and Nutrition Examination
Survey (NHANES) III [39] database and 1 standard deviation
decrease in BMD was associated with an increase in age-
adjusted relative risk of 1.8, 1.4 and 1.6 for clinical vertebral,
wrist and other fracture, respectively [40]. For hip fracture, the
age-adjusted relative risk ranged from 3.68 at 50 years to 1.93
at 85 years [41]. So, for example, the relative risks of fracture,
for men aged 73 years with a BMD of 0.627 (g/cm2) at the
femoral neck, were estimated at 1.683, 1.529, 1.330 and 1.440
at the hip, clinical vertebral, wrist and other fracture, respec-
tively. The relative risks for men with PVFs were taken from a
meta-analysis and were 2.3, 4.4, 1.4 and 1.8 for hip, clinical
vertebral, wrist and other fractures, respectively [42]. These
relative risks were reduced by 10% each per decade above the
age of 70 years [43]. An increased risk of subsequent fractures
was also modelled during the simulation for men who have a
prior fracture of the same location, using a previously de-
scribed method [18].
Strontium ranelate
The MALEO Trial has been developed in accordance with
European guideline on clinical investigation of medicinal
products (November 2006). This guideline deals with min-
imal requirement for marketing indication of a treatment in
osteoporosis in men at increased risk fracture once the
marketing indication in PMO women has been already
granted to the same drug. The MALEO Trial is a controlled
study versus placebo on the basis of calcium/vit D supple-
mentation with BMD measure as primary efficacy criteria
and a main analysis after 1 year.
In the MALEO Trial [15], a marked increase in the mean
lumbar L2–L4 and femoral neck BMD was observed in men
with high risk of fractures, similar to that previously observed
in women (Table 2). Considering these results and the previ-
ously established relationship between change in BMD and
reduction in the risk of vertebral and hip fractures with stron-
tium ranelate in women [44, 45], a similar anti-fracture effica-
cy is expected in men. We therefore assumed, in the base-case
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analysis, the same relative risk reduction of fractures in men as
those estimated in women (SOTI and TROPOS trials).
In most cost-effectiveness analyses, efficacy data were
retrieved from the entire population of the randomized clin-
ical trials and the modelers charged the full treatment cost.
Although, in real-life settings, adherence is far from optimal,
this assumption may be incorrect to estimate the potential
economic value of a drug and probably underestimates the
true underlying risk reduction with therapy since the effica-
cy from these trials is reduced to some degree because of
non-adherence. In the SOTI and TROPOS trials, adherence
was collected and per protocol studies including patients
with high level of adherence were conducted. The Per
Protocol Set strontium (PPS strontium) included all patients
from the FAS satisfying a minimum exposure condition
based on blood strontium levels criteria. In this analysis,
efficacy data from intent-to-treat [5, 7] and per-protocol
analyses (unpublished data, internal reports SOTI and
TROPOS 3-year results) were both tested.
In the base-case analysis, fracture risk reductions were
derived from the FAS of the TROPOS and SOTI trials.
Strontium ranelate was assumed in this scenario to reduce
the risk of hip, wrist and other non-vertebral fractures by
19 % (RR=0.81; 95 % confidence interval [CI], 0.66–0.98)
using the estimated fracture risk reduction for major non-
vertebral fractures [7] and the risk of clinical vertebral
fracture by 38 % (RR=0.62; 95 % CI, 0.47–0.83) [5]. We
took a conservative position for the efficacy of strontium
ranelate on hip fracture since the results of a post hoc
analysis in high-risk women aged over 74 years of age
was not incorporated [7]. In the additional scenario, the
efficacy of strontium ranelate on non-vertebral fractures
was derived from the per-protocol study of the TROPOS
Trial including 2,935 osteoporotic women above 70 years of
age with high adherence. In this population, strontium rane-
late was shown to reduce the risk of hip fracture, as com-
pared to placebo and over 3 years, by 41 % (95 % CI, 5–
63 %; p=0.025). The risk of any major non-vertebral frac-
tures, used in the model for wrist and other fractures, was
reduced by 35 % (95 % CI, 16–49 %; p<0.001) in the same
population. In the per-protocol study conducted in the SOTI
trial and including 1,076 women with a mean age of
69 years, the risk of vertebral fracture was reduced by
45 % (95 % CI, 25–57 %; p<0.001).
Patients received treatment in the base-case model for
3 years with the full effect of the treatment during the whole
intervention period. After stopping therapy, the effect of
strontium ranelate on fracture risk was assumed to decline
linearly to zero for a period (called offset time) similar to the
duration of therapy in line with a clinical study [46] and
prior cost-effectiveness analyses [14]. In a sensitivity anal-
ysis, we assessed the impact of poor adherence with stron-
tium ranelate using the same assumption than in prior cost-
effectiveness analyses of strontium ranelate in postmeno-
pausal women [12, 13]. In these analyses, adherence to
strontium ranelate was similar to that observed for
bisphosphonate therapy in Belgian women [47]. We there-
fore assumed that 30 %, 12 %, 18 % and 15 % of patients
discontinued therapy after 3 months, 6 months, 1 year and
2 years, respectively. No treatment effect was assumed for
patients who discontinued treatment at 3 months and offset
time for non-persistent patients was assumed to be the same
as their treatment period. Compliance was estimated at
70.5 % for persistent women [47]. Medication costs and
fracture reduction efficacy were assumed to be proportional
to compliance.
The annual cost of strontium ranelate was estimated at
€477.2 (Protelos®, €109.82 for a package of 84 sachets)
[48], and we assigned the cost of one physician visit
(€22.67) per year of treatment and the cost of one bone
density measurement (€58.05) every secondyear. Adverse
events with strontium ranelate are usually mild and tran-
sient. In pooled data from the SOTI and TROPOS trials [5,
7], treatment with strontium ranelate, however, was associ-
ated with an increase in the annual incidence of VTE,
including pulmonary embolism (PE). To account for this
in the analysis, VTE was included as a health state in the
model during treatment with strontium ranelate. The annual
absolute risk of VTE with strontium ranelate was estimated
at 0.31 % in women [5, 7]. In the model, VTE was assumed
to be associated with a 10 % utility loss the first year after
the event and any utility loss in the second or following
years after the event, in agreement with previous health
economic publications [49, 50]. The survival rate after PE
was estimated at 81.6 % in the clinical trials [5, 7]. Using
Belgian estimates of resource utilization based on panel
experts [51], the cost of VTE was estimated at €2,622.
Simulation and analyses
Microsimulations were performed to estimate the cost-
effectiveness of strontium ranelate. Each model was run
ten times with 200,000 trials (patients) to guarantee the
stability of the results and enable variability analyses [23].
For each analysis, the incremental cost-effectiveness ratio
(ICER) was computed as the difference between strontium
ranelate and no treatment in terms of total costs (expressed
in €2,010) divided by the difference between them in terms
of effectiveness, expressed in accumulated QALYs. It rep-
resents the cost of strontium ranelate (compared with no
treatment) per one QALY gained. In Belgium, as in many
other countries, no threshold values for ICERs have been
defined [52]. Commonly accepted thresholds for cost-
effectiveness are in the range of €50,000 [11].
Uncertainty related to model parameters and assumptions
was investigated using deterministic and probabilistic
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sensitivity analyses. Deterministic sensitivity analyses were
performed to evaluate the impact of single parameter varia-
tions on the results. The baseline parameters for discount
rates, fracture risk, fracture disutility, fracture cost and ex-
cess mortality were varied over plausible ranges. Changes in
therapy cost, monitoring cost, adverse events, offset time
and time horizon were also evaluated.
Probabilistic sensitivity analyses were performed with
200 simulations to analyze the effects of uncertainty in all
model parameters simultaneously. Distributions used for
key model inputs are provided in Table 1. Log-normal
distributions were also assumed for fracture risk reduction
with strontium ranelate. Cost-effectiveness acceptability
curves were then constructed from the incremental cost
and QALYs between alternatives for the 200 simulations.
They show the probability that strontium ranelate is cost-
effective compared with no treatment for a range of decision
makers’ willingness to pay per QALY.
Results
The lifetime costs, QALYs and ICERs of strontium ranelate
compared with no treatment are presented on Table 3 in men
Table 2 Between treatment comparison of the percentage change in lumbar spine and femoral neck BMD to month 12 relative to baseline in male
patients from MALEO and in postmenopausal women in SOTI-TROPOS studies
Relative change from baseline to M12 Men with osteoporosis PMO women
MALEO N=261 (15) TROPOS N=5,091 (7) SOTI N=1,649 (5)
Lumbar spine BMD N 197 3807 1361
E (SE) 6.2 (0.8)% 7.0 (0.2)% 7.2 (0.4)%
95 % CI [4.7–7.8] [6.6–7.4] [6.5–7.9]
p value p<0.001 p<0.001 p<0.001
Femoral neck BMD N 178 3,759 1,326
E (SE) 3.2 (0.7)% 3.6 (0.2)% 3.3 (0.2)%
95 % CI [1.8–4.6] [3.3–3.9] [2.8–3.8]
p value p<0.001 p<0.001 p<0.001
N number of patients with evaluation at both baseline and M12 visits, E (SE) estimate and standard error of the adjusted mean difference (strontium
ranelate vs. placebo), CI confidence interval of the estimate, PMO Post-menopausal osteoporosis
Table 3 Lifetime costs, QALYs and incremental cost-effectiveness ratio (cost in € per QALY gained) of strontium ranelate versus no treatment
according to population and anti-fracture efficacy
No treatment Strontium ranelate
ITT PPS
MALEO trial (i.e., BMD T-score of −2.2; 28.1 % prevalent vertebral fracture)
Costs, € 6,765 7,907 7,594
QALYs 7.2156 7.2385 7.2504
ICER, €/QALY 95 % CI 49,798 (48,561–51,035) 25,584 (24,138–27,030)
BMD T-score ≤−2.5 (and no prior fracture)
Costs, € 8,450 9,333 8,815
QALYs 7.1970 7.2222 7.2396
ICER, €/QALY 95 % CI 36,270 (34,363–38,177) 8,230 (7,672–8,888)
Prevalent vertebral fracture
Costs, € 6,189 7,325 7,063
QALYs 7.1805 7.2053 7.2204
ICER, €/QALY 95 % CI 42,359 (40,210–44,507) 22,895 (21,267–24,522)
ICER is defined as the difference between strontium ranelate and no treatment in terms of costs divided by the difference between them in terms of
QALYs
BMD bone mineral density, CI confidence interval of the estimate, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, ITT
intention-to-treat (entire population of the clinical trials), PPS per protocol studies (including only patients with high adherence)
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with similar characteristics than those included in theMALEO
Trial. Based on anti-fracture efficacy derived from the entire
population of the clinical trials, strontium ranelate compared
with no treatment was estimated at €49,798/QALY gained.
This value decreased to €36,270 and to €42,359 in men with a
BMD T-score ≤−2.5 (and no prior fractures) and with PVFs at
baseline, respectively. Using anti-fracture efficacy from the
per-protocol analyses, the cost per QALY gained of strontium
ranelate decreased in all simulated populations and remained
below a threshold of €30,000 per QALY gained.
The results of this study were sensitive to adherence to
therapy (Fig. 1). When assuming adherence similar to
bisphosphonate’s adherence for postmenopausal women, the
costs per QALY gained of strontium ranelate versus no treat-
ment were respectively €58,117, and €75,867 per QALY
gained in men with a BMD T-score ≤−2.5 and PVF using
the anti-fracture efficacy from the intent-to-treat analysis.
Additional deterministic sensitivity analyses were con-
ducted in men with a BMD T-score ≤−2.5 aged 73 years
using the anti-fracture efficacy from the intent-to-treat anal-
ysis (Fig. 2). They showed the estimated ICERs to be
modestly sensitive to changes in fracture disutility and frac-
ture cost and quite sensitive to discount rates and changes in
fracture risk or mortality excess. The ICERs decreased by
24 % for lower drug cost (−15 %) and by 38 % when
fracture risk was increased by 25 %. The ICER was also
reduced when assuming no adverse events or no monitoring
cost with strontium ranelate.
The results of the probabilistic sensitivity analyses are
presented as cost-effectiveness acceptability curves in
Fig. 3. The curves indicate the probability that strontium
ranelate is cost-effective as a function of the decision mak-
er's willingness to pay per one QALY gained. At an assumed
willingness to pay of €45,000 per QALY, strontium ranelate
was cost-effective in 62.0 % and 93.0 % of the simulations
for men aged 73 years with a BMD T-score ≤−2.5 aged
using efficacy data from the entire population of the clinical
trials and from the per-protocol analyses, respectively.
Discussion
The results of this study suggest that, under the assumption
of same relative risk reduction of fractures in men as for
women, strontium ranelate is cost-effective compared with
no treatment, at commonly accepted thresholds, for men
who are similar to patients included in the MALEO Trial.
This study provides the first pharmacoeconomic evalua-



















Adherence similar to bisphosphonate's therapy
Fig. 1 Potential impact of medication adherence on the cost per QALY
gained of strontium ranelate compared with no treatment in men with
osteoporosis or prevalent vertebral fracture. BMD bone mineral density
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Base case: 36,270 per QALY
Fig. 2 Tornado diagram for deterministic sensitivity analyses on the
cost-effectiveness of strontium ranelate compared with no treatment in
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Fig. 3 Cost-effectiveness acceptability curves of strontium ranelate
compared with no treatment in men aged 73 years with BMD T-score
≤−2.5 according to anti-fracture efficacy. ITT intention-to-treat, PPS
per protocol studies
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studies have shown that strontium ranelate was cost-
effective for post-menopausal women with low BMD
[10–14]. Treatment with strontium ranelate was compared
with no treatment. Other treatments have been approved for
the treatment of male osteoporosis. Data are currently lim-
ited on the cost-effectiveness of treating male osteoporosis
[53]. In a Swedish setting, treating osteoporotic men with
alendronate was shown to be cost-effective versus placebo
under the assumption of the same anti-fracture efficacy of
alendronate for men as for women [54]. In another analysis,
the threshold probability for cost-effective treatment ($500
per year, 35 % efficacy) was a 10-year risk of hip fracture
that ranged from 2 % at the age of 50 years to 6.5 % at the
age of 80 years [55]. Comparison with other drugs could be
performed in the future as it was done in women using
indirect comparison [12]. These would, however, be much
more uncertain than in women because, in addition to un-
certainty associated with indirect comparison of efficacy
between drugs, there would be uncertainty about the as-
sumption of the same relative risk reduction of fractures in
men as for women.
There are some potential limitations to our study that
provide uncertainty in the overall results. First, there is no
anti-fracture efficacy data of strontium ranelate in the male
population. The MALEO Trial was a bridging study and
therefore did not represent the gold standard demonstration
of anti-fracture efficacy. In accordance with the European
guidelines on clinical investigation of medicinal products,
the MALEO trial was a controlled study versus placebo with
BMD measure as primary efficacy criteria. Similar efficacy
data on lumbar spine and femoral neck (FN) BMD between
men with osteoporosis at high risk of fracture (MALEO trial
[15]) and PMO women (pivotal SOTI, TROPOS trials [5,
7]), however, supports the assumption, in the base-case
analysis, of the same relative risk reduction. In addition,
the anti-fracture efficacy of strontium ranelate verified in
PMO women whatever the baseline characteristics [56] and
whatever the 10-year fracture probabilities [57] as well as
the relationship between BMD increase and fracture risk
reduction [44, 45] reinforce this assumption.
Second, even using efficacy data from the entire popula-
tion of the clinical trials, the cost-effectiveness of the drug in
real-life settings could be altered. Many studies have
reported that adherence with osteoporosis medications is
poor and suboptimal [58], and this may impact on the
cost-effectiveness of therapies [21, 59]. A sensitivity analy-
sis assuming adherence similar to bisphosphonate’s adher-
ence for postmenopausal women confirms the potential
impact of poor adherence on cost-effectiveness. Further
research, however, would be required to estimate the cost-
effectiveness of strontium ranelate in male osteoporosis in
real-life settings. This will imply the collection of adherence
data with strontium ranelate in male patients as well as on
the relationship between poor adherence and fracture risk in
men. Additional analyses evaluating the cost-effectiveness
of strontium ranelate according to absolute fracture risk
would also be valuable. It has been increasingly suggested
that treatment should be based on absolute fracture risk
rather than on BMD threshold [60]. Although anti-
osteoporosis treatment are not yet reimbursed based on
absolute fracture risk, the development of FRAX® tool,
recently available in Belgium [24], would help to identify
new high-risk populations of men that could be treated cost-
effectively by strontium ranelate.
Third, although most of the data were collected from
male populations, some of these were derived from studies
that were composed mainly of postmenopausal women. So,
the impact of fractures on quality of life has not been
specifically investigated in populations of men and would
require further investigation. The decrease in quality of life
due to osteoporotic fractures in men, however, appears
comparable to that caused by postmenopausal osteoporotic
women [61, 62].
In addition, our analysis was performed from a
payer’s perspective rather than a societal one, in accor-
dance with Belgian methodological guidelines for phar-
macoeconomic evaluations [32]. Non-hip fracture costs
were also restricted to acute hospitalization cost but care
typically extend beyond this (e.g., drugs, doctors, home
care). Taking indirect costs such as productivity losses
and other care costs into account would improve the
cost-effectiveness of strontium ranelate as sensitivity
analysis showed that cost-effectiveness improved with
higher fracture costs. Conservative assumption was also
used for the costs of vertebral fractures as they were
calculated from a relationship between fractures in 1995
[36], and treatment of vertebral fractures has become
more expensive in recent years due to an increasing
number of surgical procedures [63].
Finally, the generalizability of our results to other
settings may be uncertain since the incidence of the
disease, the availability of health resources, clinical
practice patterns and relative prices may substantially
differ between countries and could impact on the cost-
effectiveness [64]. Cost-effectiveness analysis should
ideally be performed in each specific country with local
data. However, it is likely that strontium ranelate will
also confer cost-effective benefits, compared with no
treatment, in countries with similar characteristics than
those retained in this analysis.
In conclusion, under the assumption of the same relative
risk reduction of fractures in men as for women, this cost-
effectiveness analysis suggests that strontium ranelate has
the potential to be a cost-effective strategy compared with
no treatment for men with osteoporosis from a healthcare
payer perspective.
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